Cantargia's strategy is to obtain an extensive patent protection for its current and future product candidates. Cantargia now has patent protection for the treatment of a number of different cancer forms using antibodies against IL1RAP. Cantargia also has a patent application pending for CAN04 and variants on this molecule, plus an application for other antibodies targeting IL1RAP. Cantargia's patent strategy is global yet at the same time focused on the markets deemed most important for the different patent families.
|Patent family||Patent application||Approved patents||Validity|
|Hematological cancers||Australia, Canada, China, Europe, Israel, Japan, Mexico, South Africa, USA||Australia, China, Europe (France, Italy, Netherlands, Switzerland, Spain, Great Britain, Germany), Japan, Mexico, South Africa, USA||2030|
|Solid tumors||Australia, Brazil, Canada, China, Europe, Japan, Mexico, Russia, South Korea, USA||Europe (Belgium, Denmark, France, Ireland, Italy, Netherlands, Poland, Switzerland, Spain, Sweden, Germany, Austria), Japan, USA, Russia||2032|
|CAN04||Australia, Brazil, Europe, India, Israel, Japan, Canada, China, Mexico, Russia, Singapore, South Africa, South Korea, USA||Europe, USA||2035|
|CAN01 & CAN03||Australia, Brazil, Europe, India, Japan, Canada, China, Mexico, South Korea, USA||National phase examination in progress||2035|